Document Detail


Analysis of placental tissue in Fabry disease with and without enzyme replacement therapy.
MedLine Citation:
PMID:  20189642     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There are only a few reports on the histology of placental tissue of pregnancies from mothers with Fabry disease. Fabry disease is a lysosomal disorder caused by alpha-galactosidase A deficiency. Extensive glycosphingolipid (GSL) accumulation in fetal and maternal placenta tissue obtained from a Fabry mother and her affected male newborn has previously been reported. Here we report the evaluation of placenta tissue of two pregnancies in Fabry mothers, one of an unaffected male newborn (placenta A) and one of an affected female newborn (placenta B). The mother of the female affected offspring was treated with recombinant alpha-galactosidase A (enzyme replacement therapy, ERT) during the pregnancy (placenta B). Storage material was only detected in smooth muscle cells of the umbilical cord of placenta B. No accumulation was seen in both placentae. Combing these results with the outcome in two earlier described placentae, a heterogeneous picture emerges. This may be due to differences in disease severity in the mothers or severity of disease in their offspring. In addition, a possible effect of ERT on placental GSL accumulation could also explain lack of GSL storage in placenta B.
Authors:
M G Bouwman; C E M Hollak; M A van den Bergh Weerman; F A Wijburg; G E Linthorst
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2010-03-01
Journal Detail:
Title:  Placenta     Volume:  31     ISSN:  1532-3102     ISO Abbreviation:  Placenta     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-12     Completed Date:  2010-06-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006349     Medline TA:  Placenta     Country:  England    
Other Details:
Languages:  eng     Pagination:  344-6     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Department of Paediatrics, Emma Children's Hospital, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Enzyme Replacement Therapy*
Fabry Disease / drug therapy*,  genetics
Female
Glycosphingolipids / metabolism*
Humans
Infant, Newborn
Isoenzymes / therapeutic use
Male
Placenta / enzymology,  metabolism*
Pregnancy
Pregnancy Complications / metabolism*
Umbilical Cord / metabolism*
alpha-Galactosidase / therapeutic use
Chemical
Reg. No./Substance:
0/Glycosphingolipids; 0/Isoenzymes; EC 3.2.1.-/agalsidase beta; EC 3.2.1.22/alpha-Galactosidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Synthesis, biocompatibility and cell labeling of l-arginine-functional beta-cyclodextrin-modified qu...
Next Document:  Intracellular Ca(2+) storage in health and disease: A dynamic equilibrium.